Oklahoma City, United States
Progentec Diagnostics, Inc., established in 2015, is at the forefront of utilizing biomarker and digital technologies for the proactive care of autoimmune diseases. The company's mission focuses on addressing significant gaps in diagnostics within the Biotechnology and Health Care sectors. Their efforts aim to enhance early detection and reduce disease incidence through cutting-edge technologies.
The company's strategic collaborations with global research institutions highlight its commitment to harnessing innovations for practical diagnostics advancements. Progentec Diagnostics operates out of the United States, and its approach underscores not only improved disease management but also cost-efficient healthcare solutions.
The firm's most recent funding event was a $5.00M Series A investment on 09 January 2020. Key investors, including OCA Ventures, Mayo Clinic Ventures, and Stanford University, demonstrate robust confidence in the company's potential to transform healthcare diagnostics.
